Aprea Therapeutics Inc - Asset Resilience Ratio

Latest as of June 2019: 0.00%

Aprea Therapeutics Inc (APRE) has an Asset Resilience Ratio of 0.00% as of June 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Aprea Therapeutics Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$0.00
Cash + Short-term Investments

Total Assets

$62.21 Million
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2018)

This chart shows how Aprea Therapeutics Inc's Asset Resilience Ratio has changed over time. See APRE net asset quality score to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Aprea Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see APRE company net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $0.00 0%
Total Liquid Assets $0.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: Aprea Therapeutics Inc maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company maintains a balanced mix of cash and short-term investments.

Aprea Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Aprea Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
Biotechnology -55.36%
Krystal Biotech Inc
NASDAQ:KRYS
Biotechnology 23.06%
Verona Pharma PLC ADR
NASDAQ:VRNA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
BB Biotech AG
SW:BION
Biotechnology 0.05%

Annual Asset Resilience Ratio for Aprea Therapeutics Inc (2017–2018)

The table below shows the annual Asset Resilience Ratio data for Aprea Therapeutics Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2018-12-31 0.00% $0.00 $66.02 Million --
2017-12-31 0.00% $0.00 $24.76 Million --
pp = percentage points

About Aprea Therapeutics Inc

NASDAQ:APRE USA Biotechnology
Market Cap
$9.66 Million
Market Cap Rank
#27268 Global
#5568 in USA
Share Price
$0.78
Change (1 day)
+6.92%
52-Week Range
$0.59 - $2.08
All Time High
$990.60
About

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tum… Read more